Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers
Diabetic Foot & Ankle · 2018
DOI: 10.1080/2000625x.2018.1480249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetic Foot & Ankle, 2018. Verfasst von Martin Romero Prada und 5 weiteren Autor:innen. Beteiligte Einrichtung: Public Health in Fundacion Salutia, Center in Health Economics Investigator, Bogotá D.C., Colombia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Praxis Pharmaceutical.
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Introduction
Diabetic foot ulcers are one of the most frequent complications of diabetes; such ulcers cause an increase in the costs of the health care of the diabetic patient and can even cause disability due to amputation in the patient. Although a proportion of patients achieve a spontaneous closure of ulcers, others require medical or surgical treatment.
Objective
To determine the cost-effectiveness of the intra- and perilesional application of recombinant human epidermal growth factor (rhEGF), as opposed to conventional therapy for the management of patients diagnosed with Wagner's 3 or 4 diabetic foot ulcer in Colombia. Methodology: Using a Markov model, the process of care of a diabetic patient with diagnosis of Wagner's 3 or 4 ulcer receiving conventional treatment, or intra- and perilesional rhEGF, is configured. The evaluation cycles of the treatments are weekly over a 5-year horizon and the outcomes evaluated are quality-adjusted life years (QALYs) and the number of amputations avoided by each treatment scheme, in addition to the total costs for treatments.
Results
For the analysed base case, in the outcome of amputations, it was found that the factor presents 39 fewer amputations, in a cohort of 100 patients, compared with conventional treatment. Likewise, QALYs are 0.65 more with the use of rhEGF in an average patient. The estimated cost-utility ratio for the base case would be below the threshold established for Colombia.
Conclusions
The intra- and perilesional application of rhEGF is a more effective therapeutic option than conventional therapy in the treatment of patients with Wagner's 3 or 4 diabetic foot ulcers and is cost-effective, taking as an outcome the QALYs for Colombia from the perspective of the health system.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Public Health in Fundacion Salutia, Center in Health Economics Investigator, Bogotá D.C., Colombia.
- Health Economics and management, Universitat Politècnica de València (UPV), Valencia, España.
ORCID-Profile: Martin Romero Prada, David Vivas-Consuelo
Förderung
- Praxis Pharmaceutical
Zitieren
APA
Romero Prada, M., Roa, C., Alfonso, P., Acero, G., Huérfano, L., & Vivas-Consuelo, D. (2018). Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers. Diabetic Foot & Ankle. https://doi.org/10.1080/2000625x.2018.1480249
Vancouver
Romero Prada M, Roa C, Alfonso P, Acero G, Huérfano L, Vivas-Consuelo D. Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers. Diabetic Foot & Ankle. 2018. doi:10.1080/2000625x.2018.1480249
BibTeX
@article{RomeroPrada2018,
author = {Romero Prada, Martin and Roa, Carolina and Alfonso, Pamela and Acero, German and Huérfano, Lina and Vivas-Consuelo, David},
title = {Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers},
journal = {Diabetic Foot & Ankle},
year = {2018},
doi = {10.1080/2000625x.2018.1480249}
}
EUVIMED